| Jul 1 |
G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
|
| Jun 25 |
G1 Therapeutics drops as breast cancer therapy fails in late-stage trial
|
| Jun 25 |
G1 Therapeutics discontinue COSELA in TNBC following Phase III flop
|
| Jun 24 |
G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty
|
| Jun 24 |
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
|
| Jun 7 |
It's Probably Less Likely That G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Will See A Huge Pay Rise This Year
|
| Jun 5 |
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| May 31 |
G1 Therapeutics (NASDAQ:GTHX shareholders incur further losses as stock declines 19% this week, taking three-year losses to 84%
|
| May 28 |
G1 Therapeutics slips after new breast cancer data for lead asset
|
| May 28 |
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
|
